During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

Invited discussant Elizabeth Plimack, MD, MS, deputy director of the Fox Chase Cancer Center at Temple Health in Philadelphia, said that the absolute DFS and OS benefits seen with nivolumab in ...

Renal cell carcinoma has different subtypes ... Some checkpoint inhibitors include Keytruda (pembrolizumab), Opdivo (nivolumab), Bavencio (avelumab), and Yervoy (ipilimumab).

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

A comprehensive study of effective responses as well as resistant responses to a kidney cancer anti-PD-1 therapy found specific immune features that could provide new targets to improve cancer ...

More information: Vladimir Roudko et al, Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer, Journal for ImmunoTherapy ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.

The CheckMate -816 trial shows nivolumab plus platinum-doublet chemotherapy significantly improves overall survival in resectable non-small cell lung cancer.